CASI Pharmeceuticals

View All

About Us

CASI is a U.S. based pharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, U.S., and throughout the world. We are a NASDAQ-listed company, with offices in Rockville, Maryland, and a wholly owned subsidiary in Beijing, China through which substantially all of our operations are conducted.

Our mission is to become an integrated pharmaceutical company with significant market share in China, while establishing partnerships for global development and commercialization. Part of our strategy is to leverage our expertise and resources in China and the U.S. to bring high-quality pharmaceuticals and innovative oncology products to patients and to develop them faster and more cost-effectively using our dual China-U.S. development approach.

Learn More

Presentation

Corporate Presentation - BIO CEO & Investor Conference

Download →

Presentation

Annual Meeting Presentation

Download →

Presentation

Clinical Safety and Efficacy of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated, Locally Advanced or Metastatic Triple-Negative Breast Cancer

Download →

Receive press releases via email